Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2023 07:00 ET | Source: Pluri Inc.

Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products

Breakthrough system substantially increases cell production, with the potential to reach much higher productivity driven by platform’s significant scalability Flexible, industrial scale cell...
March 13, 2023 08:00 ET | Source: Pluri Inc.

Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity

HAIFA, Israel, March 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company,...
December 22, 2022 07:00 ET | Source: Pluri Inc.

Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept

Milestones over the last year include launch of new Company strategy, joint venture with Tnuva Group in the field of cultivated meat and additional biologics technology partnership;Joint venture with...
December 15, 2022 16:05 ET | Source: Pluri Inc.

Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

HAIFA, Israel, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, announced today that it has signed securities...
November 10, 2022 07:00 ET | Source: Pluri Inc.

Pluri wins BioTech Breakthrough Cell Innovation of the Year Award

HAIFA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company” (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company,...
October 31, 2022 08:00 ET | Source: Pluri Inc.

Pluri to Present and Participate in Upcoming Conferences

HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”)(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company,...
September 29, 2022 07:00 ET | Source: Pluri Inc.

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates

New company strategy will reduce cash burn by approximately 30%, with $56M in cash on consolidated balance sheetLeading European manufacturer of active pharmaceutical ingredients (APIs) to use Pluri’s...
September 06, 2022 07:00 ET | Source: Pluri Inc.

€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri’s PLX-PAD Cells for Osteoarthritis Treatment

HAIFA, Israel, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company,...
July 25, 2022 07:00 ET | Source: Pluri Inc.

Pluri CEO Issues Shareholder Update

HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company,...
July 25, 2022 01:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

As of July 26, 2022, Pluri’s stock will trade under the symbol PLURThe new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing...